Sylvia is an experienced biotech industry professional with over ten years of experience in the sector. Prior to joining the T1D fund, she was a Principal on the investment team at Omega Funds, where she focused on early stage investments and company creation across various therapeutic areas including neurology, immunology and rare diseases. She also served as a Board observer for Vanqua Bio, Aerium Therapeutics and Rectify Pharma.

Prior to Omega Funds, Sylvia spent almost 7 years at Ra Pharmaceuticals, a peptide drug discovery company focused on rare diseases associated with complement dysregulation. At Ra, she was involved in the early development of the company’s discovery platform, as well as developing preclinical and translational models for first-in-human studies of its lead product, Zilucoplan, which was recently approved in various countries for generalized myasthenia gravis (gMG). She also provided scientific leadership for multiple discovery programs within the company’s internal pipeline and in collaboration with Merck.

Sylvia earned her Ph.D in Biochemistry Summa Cum Laude from the University Pierre-and-Marie-Curie in Paris, France, while being a full-time visiting fellow in the Department of Genetics at Harvard University where she worked in synthetic biology. She holds an M.S. from Pierre-and-Marie-Curie University in Paris, France and a B.S. in Biochemistry from Joseph-Fourier University in Grenoble, France.

Brady Bohrmann is a venture investor and operating executive with more than 30 years of experience investing in and building innovative information technology and biotechnology companies. He is currently a Managing Director at Avalon Ventures, where he focuses on early-stage information technology investments, and previously co-founded Masthead Venture Partners. Earlier in his career, he served as President and COO of Watson Technologies and as CFO of Alpha-Beta Technology, bringing both operational and financial leadership to growth-stage companies. He became involved with Breakthrough T1D (formerly JDRF) and the T1D Fund after his son, Alden, was diagnosed with type 1 diabetes in 2013, a connection that informs his ongoing commitment to the mission. He holds a B.S. in Finance from Babson College. He serves as a member of the T1D Fund’s Investment Committee.